Floatz logo

Nivolumab

IDH1 Mutation

Jason J. Luke, MDmonoclonal_antibodyPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the IDH1 Mutation cohort.

Asset / SponsorPhaseRating
ag-120
Massachusetts General Hospital
Phase 2BB
Venetoclax
Justin Watts, MD
Phase 2B
Azacitidine
Shen yang
Phase 2B
Daunorubicin
Shen yang
Phase 2CCC
Olutasidenib
Timothy Pardee
Phase 2CCC
Cytosin-Arabinosid
Shen yang
Phase 2CCC
Pamiparib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2CCC

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →